In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3376-3383

  Cardarelli, Pina M ^a   Moldovan Loomis, Maria Cristina ^a   Preston, Ben ^a   Black, Amelia ^a   Passmore, David ^a   Chen, Tseng Hui ^a   Chen, Sharline ^a   Liu, Jie ^a   Kuhne, Michelle R ^a   Srinivasan, Mohan ^a   Assad, Albert ^b   Witte, Alison ^a   Graziano, Robert F ^a   King, David J ^c  

^a Medarex ^*  (United States)

^b Medarex   (United States)

^c AnaptysBio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD30 ANTIGEN; FUCOSE; HUMAN MONOCLONAL ANTIBODY; MDX 060; MDX 1401; MONOCLONAL ANTIBODY; PHENYLALANINE; UNCLASSIFIED DRUG; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; EFFECTOR CELL; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD30; BINDING SITES, ANTIBODY; CARBOHYDRATES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUCOSE; HUMANS; LYMPHOMA; MALE; MICE; MICE, SCID; RECEPTORS, IGG; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66149161776     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3222     Document Type: Article

References (38)

1. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 1999;112:241-247 (Pubitemid 30212541)
2. Leroy X, Augusto D, Leteurtre E, et al. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histochem Cytochem 2002;50:283-285 (Pubitemid 34106767)
3. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000;96:3681-3695
4. Ralfkiaer E, Bosq J, Gatter KC, et al. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res 1987;279:285-292 (Pubitemid 17092160)
5. de Bruin PC, Gruss HJ, van der Valk P, et al. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. Leukemia 1995;9:1620-1627
6. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large cell lymphoma. J Clin Oncol 2007;25:2764-2769 (Pubitemid 47123185)
7. + hematologic malignancies. Blood 2008;111:1848-1854.
8. Hartmann F, Renner C, Jung W, et al. Anti-CD16/ CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. Leuk Lymphoma 1998;31:385-392 (Pubitemid 29033960)
9. Borchmann P, Schnell R, Fuss I. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients withrefractory Hodgkin lymphoma. Blood 2002;100:3101-3107 (Pubitemid 35217055)
10. Schnell R, Dietlein M, Staak O, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005;23:4669-4678 (Pubitemid 46224069)
11. Carter P. Improving the efficacy of antibody-based cancer therapeutics. Nat Rev Cancer 2001;1:118-129 (Pubitemid 33741887)
12. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-357
13. Clynes RA, Takechi Y, Moroi Y, et al. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998;95:652-656 (Pubitemid 28083798)
14. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-446 (Pubitemid 30208162)
15. Nimmerjahn F, Ravetch JV. Fc receptors: old friends and new family members. Immunity 2006;24:19-28. (Pubitemid 43077197)
16. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-1070 (Pubitemid 27386289)
17. Koene HR, Kleijer M, Algra J, et al. FcγRIIIa- 158V/F polymorphism influences the binding of IgG by natural killer cell Fc γRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype. Blood 1997; 90:1109-1114 (Pubitemid 27314146)
18. Niwa R, Natsume A, Uehara A, et al. IgG subclass- independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005;306:151-160 (Pubitemid 41739846)
19. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:745-758 (Pubitemid 34525533)
20. Weng WK, Levy R. Two immunoglobulin G fragment receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-3947 (Pubitemid 46606207)
21. Weng WK, Czerwinski D, Timmerman J, et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated withh umoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004;22:4717-4742
22. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-459 (Pubitemid 36278014)
23. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006;103:4005-4010
24. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-26740
25. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-3473 (Pubitemid 36801263)
26. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 withe nhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004;64:2127-2133 (Pubitemid 38339463)
27. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005;23:1117-1125 (Pubitemid 41486393)
28. Borchmann P, Tremi JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-3742 (Pubitemid 37409395)
29. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakabo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004;97:614-622 (Pubitemid 39295406)
30. Mechetina LV, Najakshin AM, Alabyev BY, et al. Identification of CD16-2, a novel mouse receptor homologous to CD16/FcγRIII. Immunogenetics 2002;54:463-468 (Pubitemid 35231995)
31. Hatjiharissi E, Xu L, Sants DD, et al. Increased natural killer cell expression of CD16, and augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 2007;110:2561-2564 (Pubitemid 47523179)
32. Congy-Jolivet N, Bolzec A, Ternant D, et al. FcγRIIIa expression is not increased on natural killer cells expressing the FcγRIIIa-158V allotype. Cancer Res 2008;68:976-980
33. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low affinity Fcγ receptors in two control populations and a review of low affinity Fcγ receptor polymorphisms in control and disease populations. Blood 1999;94:4220-4232
34. Niwa R, Sakurada M, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005;11:2327-2336 (Pubitemid 40490194)
35. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005;310:1510-1512 (Pubitemid 41746349)
36. Nimmerjahn F, Bruhns P, Horiuchi K, et al. FcγRIV: a novel receptor withd istinct IgG subclass specificity. Immunity 2005;23:41-51. (Pubitemid 41019656)
37. Zhang M, Yao Z, Zhang Z, et al. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood 2006;108:705-710 (Pubitemid 44061373)
38. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-auristatin- E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008;142: 69-73.